학술논문
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Document Type
Article
Author
Lorusso, D.; Pisano, C.; Zamagni, C.; Mouret-Reynier, M.-A.; Lebreton, C.; Bourgeois, H.; Hardy-Bessard, A.-C.; Fabbro, M.; Berton, D.; Lotz, J.-P.; Gladieff, L.; Abadie-Lacourtoisie, S.; Pujade-Lauraine, E.; Ray-Coquard, I.; Harter, P.; Fasching, P.A.; Runnebaum, I.; Schnelzer, A.; Schmalfeldt, B.; Belau, A.; Gropp-Meier, M.; Lück, H.-J.; Cropet, C.; Caballero, C.; Manso, L.; Wolfrum-Ristau, P.; Satoh, T.; Vergote, I.; Parma, G.; Nøttrup, T.J.
Source
In: International Journal of Gynecological Cancer . (International Journal of Gynecological Cancer, 21 December 2023, 34(4):550-558)
Subject
Language
English
ISSN
15251438
1048891X
1048891X